International Journal of Hematology

, Volume 83, Issue 2, pp 159–163 | Cite as

Single-Dose Daily Infusion of Cyclosporine for Prevention of Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation from HLA Allele-Matched, Unrelated Donors

  • Yuichiro Nawa
  • Masamichi Hara
  • Kazushi Tanimoto
  • Koichi Nakase
  • Teruhiko Kozuka
  • Yoshinobu Maeda


Peak blood concentration of cyclosporine (CsA) in renal transplantation patients was recently reported to be associated with clinical efficacy.We therefore evaluated the toxicity and efficacy of a regimen of once-daily infusion of CsA plus a short course of methotrexate as prophylaxis of graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation from an HLA allele-matched, unrelated donor. Nineteen patients with hematologic malignancies received CsA, 3 mg/kg per day, as a 4-hour intravenous (IV) infusion from day -1. After engraftment, patients received CsA orally at twice the IV dose. The CsA dose was adjusted to maintain the blood trough level between 150 and 200 ng/mL. Methotrexate was administered IV at doses of 10 mg/m2 on day 1 and 7 mg/m2 on days 3, 6, and 11. Bone marrow engraftment occurred in all patients. Grade 1 and grade 2 GVHD occurred in 6 (31.6%) and 7 (36.8%) of the 19 patients, respectively. No patient had grade 3 or 4 GVHD. Acute nephrotoxicity developed in 1 (5.3%) of the 19 patients, and hypertension developed in 3 (15.8%) of the 19 patients.We evaluated the pharmacokinetics of 4-hour CsA infusion in 10 patients.The mean trough concentration, mean peak concentration, mean time to peak concentration, and area under the curve (24 hours) were 161 ± 43 ng/mL, 1498 ± 387 ng/mL, 3.2 ± 1.0 hours, and 10,848 ± 1,991 ng ± h/mL, respectively. This regimen was well tolerated and did not enhance the risk of severe GVHD in patients undergoing allogeneic bone marrow transplantation from an HLA allele-matched, unrelated donor.

Key words

CsA Short infusion Graft-versus-host disease Matched unrelated donor 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lazarus HM, Vogelsang GB, Rowe JM. Prevention and treatment of acute graft-versus-host disease: the old and the new-a report from the Eastern Cooperative Oncology Group (ECOG). Bone Marrow Transplant. 1997;19:577–600.CrossRefPubMedGoogle Scholar
  2. 2.
    Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729–735.CrossRefPubMedGoogle Scholar
  3. 3.
    Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation. 1999;68:1356–1361.CrossRefPubMedGoogle Scholar
  4. 4.
    Sindhi R, LaVia MF, Pasulling E, et al. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine + rapamycin regimen. Transplantation. 2000;69:432–436.CrossRefPubMedGoogle Scholar
  5. 5.
    Quien RM, Kaiser BA, Dunn SP, et al. Calcineurin activity in children with renal transplants receiving cyclosporine. Transplantation. 1997;64:1486–1489.CrossRefPubMedGoogle Scholar
  6. 6.
    Batiuk TD, Pazderka F, Holloran PF. Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients. Transplantation. 1995;59:1400–1404.CrossRefPubMedGoogle Scholar
  7. 7.
    Grevel J,Welsh MS, Kahan BD. Cyclosporine monitoring in renal transplantation: area under the curve monitoring superior to trough level monitoring. Ther Drug Monit. 1989;11:246–248.CrossRefPubMedGoogle Scholar
  8. 8.
    Morris RG, Russ GR, Cervelli MJ, Juneja R, McDonald SP, Mathew TH. Comparison of trough, 2-hour, and limited AUC blood sampling of monitoring cyclosporin (Neoral) at day 7 postrenal transplantation and incidence of rejection in the first month. Ther Drug Monit. 2002;24:479–486.CrossRefPubMedGoogle Scholar
  9. 9.
    Pollard SG, Lear PA, Ready AR, Moore RH, Johnson RW. Comparison of microemulsion and conventional formulations of cyclosporine in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group. Transplantation. 1999;68:1325–1331.CrossRefPubMedGoogle Scholar
  10. 10.
    Graziadei IW,Wiesner RH, Marotta PJ, et al. Neoral compared to Sandimmune is associated with a decrease in histologic severity of rejection in patients undergoing primary liver transplantation. Transplantation. 1997;64:726–731.CrossRefPubMedGoogle Scholar
  11. 11.
    Ogawa N, Kanda Y, Matsubara M, et al. Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion. Bone Marrow Transplant. 2004;33:549–552.CrossRefPubMedGoogle Scholar
  12. 12.
    Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class 1 HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med. 1998;339:1177–1185.CrossRefPubMedGoogle Scholar
  13. 13.
    Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295–304.CrossRefPubMedGoogle Scholar
  14. 14.
    Beelen DW, Quabeck K, Kaiser B, et al. Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation. 1990;50:421–427.CrossRefPubMedGoogle Scholar
  15. 15.
    Petersdorf EW, Longton GM, Anasetti C, et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A,B,DR identical unrelated donor marrow transplantation. Blood. 1995;86:1606–1613.PubMedGoogle Scholar
  16. 16.
    Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99:4200–4206.CrossRefPubMedGoogle Scholar
  17. 17.
    Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host-disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92:2303–2314.PubMedGoogle Scholar
  18. 18.
    Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96:2062–2068.Google Scholar
  19. 19.
    Miller KB, Schenkein DP, Comezo R, et al. Adjusted-dose continuous- infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol. 1994;68:15–20.CrossRefPubMedGoogle Scholar
  20. 20.
    Schultz KR, Nevill TJ, Balshaw RF, et al. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. Bone Marrow Transplant. 2000;26:545–551.CrossRefPubMedGoogle Scholar
  21. 21.
    Dotti G, Gaspari F, Caruso R, et al. Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. Haematolgica. 2001;86:311–315.Google Scholar
  22. 22.
    Schwinghammer TL, Przepiorka D, Venkataramanan R, et al. The kinetics of cyclosporine and its metabolites in bone marrow transplant patients. Br J Clin Pharmacol. 1991;32:323–328.CrossRefPubMedGoogle Scholar
  23. 23.
    Parquet N, Reigneau O, Humbert H, et al. New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 2000;25:965–968.CrossRefPubMedGoogle Scholar
  24. 24.
    Aweeka FT,Tomlanovich SJ, Prueksaritanont T,Gupta SK, Benet LZ. Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. J Clin Pharmacol. 1994;34:60–67.CrossRefPubMedGoogle Scholar
  25. 25.
    Ogata M, Ogata Y, Imamura T, et al. Successful bone marrow transplantation from an unrelated donor in a patient with adult T cell leukemia. Bone Marrow Transplant. 2002;30:699–701.CrossRefPubMedGoogle Scholar
  26. 26.
    Ljungman P, Lawler M, Asjo B, et al. Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLV-1) following allogeneic bone marrow transplantation for HTLV-1 positive adult T-cell leukemia. Br J Haematol. 1994;88:403–405.CrossRefPubMedGoogle Scholar
  27. 27.
    Ringlen O, Labopin M, Tura S, et al. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukemia. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 1996;93:637–645.CrossRefGoogle Scholar
  28. 28.
    Tallman MS, Nemunaitis JJ, Mc Guire TR, et al. Comparison of two intravenous cyclosporine infusion schedules in marrow transplant recipients. Transplantation. 1985;45:813–817.Google Scholar
  29. 29.
    Tarantino A, Passerini P, Campise M, et al. Is cyclosporine in renaltransplant recipients more effective when given twice a day than in a single daily dose? Transplantation. 2004;78:675–680.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2006

Authors and Affiliations

  • Yuichiro Nawa
    • 1
  • Masamichi Hara
    • 1
  • Kazushi Tanimoto
    • 1
  • Koichi Nakase
    • 1
  • Teruhiko Kozuka
    • 1
  • Yoshinobu Maeda
    • 1
  1. 1.Division of HematologyEhime Prefectural Central HospitalEhimeJapan

Personalised recommendations